Hexima (HXL) 주식 개요Hexima Limited는 중요한 사업을 운영하고 있지 않습니다. 자세히 보기HXL 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6강점지난 5년 동안 수입이 매년 6.6% 증가했습니다.위험 분석의미 있는 시가총액이 없습니다(A$2M)수익이 USD$1m 미만입니다(A$62K)주식은 유동성이 매우 낮습니다모든 위험 점검 보기HXL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.0132.0k% 고평가 내재 할인율Est. Revenue$PastFuture-10m6m2016201920222025202620282031Revenue AU$30.6kEarnings AU$5.7kAdvancedSet Fair ValueView all narrativesHexima Limited 경쟁사AdAltaSymbol: ASX:1ADMarket cap: AU$9.3mChimeric TherapeuticsSymbol: ASX:CHMMarket cap: AU$3.9mNoxopharmSymbol: ASX:NOXMarket cap: AU$23.4mImugeneSymbol: ASX:IMUMarket cap: AU$40.8m가격 이력 및 성과Hexima 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가AU$0.01352주 최고가AU$0.02152주 최저가AU$0.008베타0.911개월 변동0%3개월 변동0%1년 변동-18.75%3년 변동-96.53%5년 변동n/aIPO 이후 변동-93.33%최근 뉴스 및 업데이트공시 • Oct 24Hexima Limited, Annual General Meeting, Nov 27, 2025Hexima Limited, Annual General Meeting, Nov 27, 2025. Location: at the offices of qr lawyers, level 6, 400 collins street, melbourne, vic 3000, Australia공시 • Dec 04Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction.Real Thing Entertainment agreed to acquire Hexima Limited (ASX:HXL) in a reverse merger transaction for AUD 8.1 million on July 24, 2024. As per the transaction, Real Thing Entertainment will issue, 789.7 million shares to the shareholders of Hexima Limited as consideration. also issue up to 25 million shares to two RealThing shareholders to redeem two convertible notes. The proposed acquisition was subject to conditions precedent outlined in the 24 July 2024 announcement, including shareholder approvals and raising capital as part of re-compliance with the ASX Listing Rule Chapter 1 and 2 admission requirements. The transaction is expected to complete on October 9, 2024. On September 27, 2024 Hexima Limited announced the extension to the date for satisfaction of conditions precedent related to the binding but conditional Share Sale Agreement to acquire 100% of the shares of Real Thing Entertainment to December 16, 2024. Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction on December 3, 2024. The Board is unable to have sufficient confidence that the conditions precedent will be able to be satisfied, including that the requisite level of capital would be able to be raised, or the general meeting arranged to be held and the other re-compliance requirements completed, before the conditions precedent satisfaction date. The Board has formed the view that committing funds to complete the process for calling the general meeting to seek the approvals would not be appropriate in those circumstances. Accordingly, after Board consideration, the Company has given notice of termination of the share sale agreement to RealThing and the vendors in accordance with the provisions of the agreement relating to the conditions precedent.공시 • Dec 03Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listing공시 • Oct 29Hexima Limited, Annual General Meeting, Nov 29, 2024Hexima Limited, Annual General Meeting, Nov 29, 2024. Location: at the offices of william buck, level 20, 181 william street, melbourne, vic 3000 Australia공시 • Jul 25Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct ListingBoard Change • Dec 04No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). COO & Director Nicole van der Weerden is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.더 많은 업데이트 보기Recent updates공시 • Oct 24Hexima Limited, Annual General Meeting, Nov 27, 2025Hexima Limited, Annual General Meeting, Nov 27, 2025. Location: at the offices of qr lawyers, level 6, 400 collins street, melbourne, vic 3000, Australia공시 • Dec 04Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction.Real Thing Entertainment agreed to acquire Hexima Limited (ASX:HXL) in a reverse merger transaction for AUD 8.1 million on July 24, 2024. As per the transaction, Real Thing Entertainment will issue, 789.7 million shares to the shareholders of Hexima Limited as consideration. also issue up to 25 million shares to two RealThing shareholders to redeem two convertible notes. The proposed acquisition was subject to conditions precedent outlined in the 24 July 2024 announcement, including shareholder approvals and raising capital as part of re-compliance with the ASX Listing Rule Chapter 1 and 2 admission requirements. The transaction is expected to complete on October 9, 2024. On September 27, 2024 Hexima Limited announced the extension to the date for satisfaction of conditions precedent related to the binding but conditional Share Sale Agreement to acquire 100% of the shares of Real Thing Entertainment to December 16, 2024. Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction on December 3, 2024. The Board is unable to have sufficient confidence that the conditions precedent will be able to be satisfied, including that the requisite level of capital would be able to be raised, or the general meeting arranged to be held and the other re-compliance requirements completed, before the conditions precedent satisfaction date. The Board has formed the view that committing funds to complete the process for calling the general meeting to seek the approvals would not be appropriate in those circumstances. Accordingly, after Board consideration, the Company has given notice of termination of the share sale agreement to RealThing and the vendors in accordance with the provisions of the agreement relating to the conditions precedent.공시 • Dec 03Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listing공시 • Oct 29Hexima Limited, Annual General Meeting, Nov 29, 2024Hexima Limited, Annual General Meeting, Nov 29, 2024. Location: at the offices of william buck, level 20, 181 william street, melbourne, vic 3000 Australia공시 • Jul 25Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct ListingBoard Change • Dec 04No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). COO & Director Nicole van der Weerden is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Nov 29Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as DirectorHexima Limited announced that Dr. Nicole van der Weerden has resigned as a director of the company effective 28 November 2023, as she pursues other endeavours.공시 • Oct 19Hexima Limited, Annual General Meeting, Nov 28, 2023Hexima Limited, Annual General Meeting, Nov 28, 2023, at 10:00 AUS Eastern Standard Time.공시 • Sep 20Hexima Limited Appoints Phillip Hains as A Non-Executive DirectorHexima Limited announced the appointment of Phillip Hains as a Non-Executive Director, effective 18 September 2023. Mr. Hains is a Chartered Accountant with over 30 year experience. Mr. Hains has served the needs of a number of company boards, committees and management.Reported Earnings • Sep 02Full year 2023 earnings released: AU$0.011 loss per share (vs AU$0.066 loss in FY 2022)Full year 2023 results: AU$0.011 loss per share (improved from AU$0.066 loss in FY 2022). Revenue: AU$1.48m (down 74% from FY 2022). Net loss: AU$1.92m (loss narrowed 81% from FY 2022).New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.3m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 34% per year over the past 5 years. Market cap is less than US$10m (AU$3.84m market cap, or US$2.49m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.8m revenue, or US$3.1m).Recent Insider Transactions • Jun 07Insider recently bought AU$155k worth of stockOn the 5th of June, John Tarrant bought around 13m shares on-market at roughly AU$0.012 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.공시 • May 12Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate DirectorHexima Limited announced the resignation of Mr. Steven Skala as an alternate director of the Company, effective 11 May 2023.Reported Earnings • Mar 04First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.029 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.029 loss in 1H 2022). Revenue: AU$1.35m (down 42% from 1H 2022). Net loss: AU$1.55m (loss narrowed 62% from 1H 2022).공시 • Dec 22Nicole Van Der Weerden to Step Down as CEO of Hexima LimitedHexima Limited announces that Dr. Nicole van der Weerden, its Acting CEO and former COO, will step down from her executive responsibilities effective 31 December, 2022. Dr. van der Weerden will continue as a Non-Executive Director of the Company and continue to support Hexima through this transition period. This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Hexima's operational activities have been largely wound down over the past 6 months, reducing the need for a full-time CEO. The Board continues to advance its stated strategic goal of maximizing shareholder value through a transaction, supported by the Company's contract Company Secretary and contract CFO.공시 • Dec 14+ 1 more updateHexima Limited, Annual General Meeting, Jan 31, 2023Hexima Limited, Annual General Meeting, Jan 31, 2023, at 10:00 AUS Eastern Standard Time. Location: the offices of Arnold Bloch Leibler, Level 21, 333 Collins Street Melbourne Australia Agenda: To consider to remove Mr Michael Aldridge as a Director; to consider to remove Mr Jake Nunn as a Director; to consider to remove Mr Scott Robertson as a Director; and to consider appoint Mr Chris Mews as a Director.공시 • Dec 05Hexima Limited Announces Board ChangesHexima Limited announced the following board changes: The removal of Mr. Michael Aldridge as a director; The removal of Mr. Jake Nunn as a director; and the removal of Mr. Scott Robertson as a director.Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Non-Executive Chairman Jonathan West is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Oct 01+ 1 more updateHexima Limited, Annual General Meeting, Nov 16, 2022Hexima Limited, Annual General Meeting, Nov 16, 2022, at 10:00 AUS Eastern Standard Time.Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.066 loss per share (down from AU$0.061 loss in FY 2021). Net loss: AU$10.0m (loss widened 46% from FY 2021). Over the next year, revenue is expected to shrink by 100% compared to a 33% growth forecast for the Biotechs industry in Australia.공시 • Aug 02Hexima Limited Announces Management ChangesHexima Limited announced that Mr. Michael Aldridge, its Managing Director & CEO, will resign his executive responsibilities effective immediately. Nicole van der Weerden, currently Chief Operating Officer, will serve as acting CEO. Mr. Aldridge will continue as a non-executive director of the Company. This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Mr. Aldridge will not be remunerated for his role as non-executive director.공시 • Jul 12Hexima Limited Announces Phase II Results of PezadeftideHexima Limited announced the results of its phase II clinical study of pezadeftide (HXP124) for the treatment of onychomycosis (HXP124-ONY-002). HXP124-ONY-002 was designed and conducted as a phase II, multi-centre, randomized, double-blind, vehicle-controlled study to investigate the efficacy, safety and tolerability of pezadeftide (HXP124) in three dosing cohorts in patients with mild to moderate onychomycosis. Subjects were randomised to receive once daily topical application of 2% (20 mg/mL) pezadeftide or vehicle to all infected toenails in one of three cohorts (randomization 3:1 pezadeftide to vehicle): Cohort 1: 2 treatment periods of 6 weeks; N=29 pezadeftide, 9 vehicle Cohort 2: 2 treatment periods of 6 weeks plus once-weekly maintenance dosing for 23 weeks; N=30 pezadeftide, 10 vehicle Cohort 3: 5 treatment periods of 6 weeks plus 1 treatment period of 1 week; N=30 pezadeftide, 9 vehicle. A total of 117 patients were enrolled; 14 were withdrawn or dropped out prior to completing the study. Patients were assessed for safety and efficacy at scheduled visits (weeks 13, 24, 36) during the course of the study and at the final follow-up visit at week 40. Inclusion and exclusion criteria were generally consistent with those adopted in pivotal clinical studies of the leading branded topical product in the US market. There was a balanced distribution of patients between cohorts according to age, weight, height, and BMI, 80% were male, 20% female and 89% of enrolled patients were Caucasian. Completers were defined as having complied and received 85% or more of drug doses. Pezadeftide was well-tolerated and safe, with only three Serious Adverse Events (fall, angina and depression) reported and none reported as drug-related. Overall, Adverse Events (144) were primarily mild, with no unexpected Treatment Emergent Adverse Events, and were similar in reported and observed for pezadeftide and vehicle-treated patients, regardless of Cohort. The summary of efficacy as at week 40 is shown in the table below. These endpoints are the pre- defined efficacy parameters in the phase II study and are as defined by FDA. There was no consistent effect observed in pezadeftide-treated patients at week 40 compared to vehicle-treated, with the best efficacy results observed in Cohort 2.공시 • Jun 24Hexima Limited Announces Preliminary Results of Phase II Clinical Study of PezadeftideOn June 24, 2022, Hexima Limited announced that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete.Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Non-Executive Chairman Jonathan West is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.분석 기사 • Mar 21Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. By way of example, Hexima...분석 기사 • Sep 06Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Reported Earnings • Aug 29Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.028 loss in FY 2020)Full year 2021 results: Net loss: AU$6.87m (loss widened 90% from FY 2020).공시 • Jul 15Hexima Limited Extends Its Patent Protection for PezadeftideHexima Limited announced that a European patent covering the use of pezadeftide for the treatment of onychomycosis will be granted on 14 July 2021. The patent (#3209319) is described as "A Method of Treatment" and provides broad protection covering the therapeutic use of pezadeftide, as well as topical formulations containing pezadeftide, for the treatment of onychomycosis. The patent provides protection until 2035 and Hexima also expects to benefit from up to an additional five years of market exclusivity through the supplementary patent certification available for medicinal products in member states of the European Union. The award of this European patent further strengthens Hexima's patent portfolio which includes similar granted patents in the United States, Japan, Singapore and Australia. Hexima continues to pursue further patent filings in these and other jurisdictions; most recently receiving notification of the grant of "A Method of Treatment" patent (#382906) in Mexico.공시 • Apr 27Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 for the Treatment of Onychomycosis at American Podiatric Medical Association Annual ConferenceHexima Limited announced that it has been selected to present clinical data from its Phase I/IIa clinical trial of HXP 124 for the treatment of onychomycosis at the annual meeting of the American Podiatric Medical Association (APMA) in Aurora, Colorado in July 2021. The APMA represents an important venue for the presentation of HXP124's potential in onychomycosis. Podiatrists are the specialists who tend to manage most cases of onychomycosis and importantly write 80% of all prescriptions for onychomycosis in the US. Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at between 10% (Japan) and 13.8% (USA). Onychomycosis is an infectious disease with significant healthcare burden, it causes pain in approximately 50% of patients and in the US results in close to four doctor's visits annually for treatment.[3] Onychomycosis impacts a patient's quality of life with 51% unable to wear the shoes they would prefer and 66% distressed by the appearance of their nail. It is important to treat onychomycosis as the fungi in the nail and can be a source of secondary infection in other areas of the body or infect family members and spread to the environment. Onychomycosis is the most common nail disorder, and the most common skin infection, accounting for 50% of all nail diseases. It is particularly prevalent in older, diabetic and immune compromised populations. The global market for treatments for onychomycosis was approximately USD 3.7 billion in 2018. Approved prescription therapies for onychomycosis comprise either oral or topical medications. Oral medications are associated with adverse effects such as nausea, taste disturbance, and flatulence. They can also severely impact liver function and so often require liver function monitoring. The clinical and commercial success of topical medications has been constrained by an inability of anti-fungal agents to effectively penetrate the human nail and the lack of sufficient anti-fungal activity when in contact with the target pathogen.분석 기사 • Mar 02Read This Before Selling Hexima Limited (ASX:HXL) SharesWe've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...공시 • Jan 08Hexima Limited Updates Timeline to Phase 2B ResultsHexima Limited developing HXP124, a new prescription treatment for onychomycosis, announced an updated timeline to delivery of results from its phase IIb clinical trial which is being conducted in patients with onychomycosis. The pace of enrolment of patients into the trial, which is being conducted in Australia and New Zealand, has been modestly impacted by State travel restrictions, business closures and mandated lock downs due to the Coronavirus pandemic. These events have not affected in any way the integrity of the trial but are likely to result in data from the clinical trial being available one calendar quarter later than previously anticipated. Hexima has recently added additional clinical investigator sites and adopted other measures to accelerate patient recruitment and enrolment. Accordingly, Hexima expects to announce results of its phase IIb clinical trial of HXP124 in patients with onychomycosis in the second quarter of 2022.공시 • Dec 01Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.Hexima Limited has completed an IPO in the amount of AUD 3.280771 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,403,854 Price\Range: AUD 0.2주주 수익률HXLAU BiotechsAU 시장7D0%5.7%3.4%1Y-18.8%-52.4%3.6%전체 주주 수익률 보기수익률 대 산업: HXL은 지난 1년 동안 -52.4%의 수익을 기록한 Australian Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: HXL은 지난 1년 동안 3.6%를 기록한 Australian 시장보다 저조한 성과를 냈습니다.주가 변동성Is HXL's price volatile compared to industry and market?HXL volatilityHXL Average Weekly Movementn/aBiotechs Industry Average Movement11.1%Market Average Movement10.2%10% most volatile stocks in AU Market17.3%10% least volatile stocks in AU Market4.1%안정적인 주가: HXL의 주가는 지난 3개월 동안 Australian 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine HXL의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트1997n/aGeoffrey Kemplerhexima.com.au헥시마 리미티드는 큰 사업을 운영하고 있지 않습니다. 회사 자산의 가치를 높일 수 있는 제3자와의 거래 탐색에 중점을 두고 있습니다. 이전에는 손발톱 무좀 치료를 위한 페자데프타이드의 연구 개발에 참여했습니다.더 보기Hexima Limited 기초 지표 요약Hexima의 순이익과 매출은 시가총액과 어떻게 비교됩니까?HXL 기초 통계시가총액AU$2.17m순이익 (TTM)-AU$933.87k매출 (TTM)AU$61.67k35.2x주가매출비율(P/S)-2.3x주가수익비율(P/E)HXL는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표HXL 손익계산서 (TTM)매출AU$61.67k매출원가AU$0총이익AU$61.67k기타 비용AU$995.55k순이익-AU$933.87k최근 보고된 실적Jun 30, 2024다음 실적 발표일해당 없음주당순이익(EPS)-0.0056총이익률100.00%순이익률-1,514.21%부채/자본 비율0%HXL의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/01/21 16:34종가2024/10/24 00:00수익2024/06/30연간 수익2024/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hexima Limited는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Graeme WaldCanaccord Genuity Historic (Wilsons Advisory and Stockbroking Ltd.Shane StoreyCanaccord Genuity Historic (Wilsons Advisory and Stockbroking Ltd.
공시 • Oct 24Hexima Limited, Annual General Meeting, Nov 27, 2025Hexima Limited, Annual General Meeting, Nov 27, 2025. Location: at the offices of qr lawyers, level 6, 400 collins street, melbourne, vic 3000, Australia
공시 • Dec 04Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction.Real Thing Entertainment agreed to acquire Hexima Limited (ASX:HXL) in a reverse merger transaction for AUD 8.1 million on July 24, 2024. As per the transaction, Real Thing Entertainment will issue, 789.7 million shares to the shareholders of Hexima Limited as consideration. also issue up to 25 million shares to two RealThing shareholders to redeem two convertible notes. The proposed acquisition was subject to conditions precedent outlined in the 24 July 2024 announcement, including shareholder approvals and raising capital as part of re-compliance with the ASX Listing Rule Chapter 1 and 2 admission requirements. The transaction is expected to complete on October 9, 2024. On September 27, 2024 Hexima Limited announced the extension to the date for satisfaction of conditions precedent related to the binding but conditional Share Sale Agreement to acquire 100% of the shares of Real Thing Entertainment to December 16, 2024. Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction on December 3, 2024. The Board is unable to have sufficient confidence that the conditions precedent will be able to be satisfied, including that the requisite level of capital would be able to be raised, or the general meeting arranged to be held and the other re-compliance requirements completed, before the conditions precedent satisfaction date. The Board has formed the view that committing funds to complete the process for calling the general meeting to seek the approvals would not be appropriate in those circumstances. Accordingly, after Board consideration, the Company has given notice of termination of the share sale agreement to RealThing and the vendors in accordance with the provisions of the agreement relating to the conditions precedent.
공시 • Dec 03Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listing
공시 • Oct 29Hexima Limited, Annual General Meeting, Nov 29, 2024Hexima Limited, Annual General Meeting, Nov 29, 2024. Location: at the offices of william buck, level 20, 181 william street, melbourne, vic 3000 Australia
공시 • Jul 25Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listing
Board Change • Dec 04No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). COO & Director Nicole van der Weerden is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Oct 24Hexima Limited, Annual General Meeting, Nov 27, 2025Hexima Limited, Annual General Meeting, Nov 27, 2025. Location: at the offices of qr lawyers, level 6, 400 collins street, melbourne, vic 3000, Australia
공시 • Dec 04Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction.Real Thing Entertainment agreed to acquire Hexima Limited (ASX:HXL) in a reverse merger transaction for AUD 8.1 million on July 24, 2024. As per the transaction, Real Thing Entertainment will issue, 789.7 million shares to the shareholders of Hexima Limited as consideration. also issue up to 25 million shares to two RealThing shareholders to redeem two convertible notes. The proposed acquisition was subject to conditions precedent outlined in the 24 July 2024 announcement, including shareholder approvals and raising capital as part of re-compliance with the ASX Listing Rule Chapter 1 and 2 admission requirements. The transaction is expected to complete on October 9, 2024. On September 27, 2024 Hexima Limited announced the extension to the date for satisfaction of conditions precedent related to the binding but conditional Share Sale Agreement to acquire 100% of the shares of Real Thing Entertainment to December 16, 2024. Real Thing Entertainment cancelled the acquisition of Hexima Limited (ASX:HXL) in a reverse merger transaction on December 3, 2024. The Board is unable to have sufficient confidence that the conditions precedent will be able to be satisfied, including that the requisite level of capital would be able to be raised, or the general meeting arranged to be held and the other re-compliance requirements completed, before the conditions precedent satisfaction date. The Board has formed the view that committing funds to complete the process for calling the general meeting to seek the approvals would not be appropriate in those circumstances. Accordingly, after Board consideration, the Company has given notice of termination of the share sale agreement to RealThing and the vendors in accordance with the provisions of the agreement relating to the conditions precedent.
공시 • Dec 03Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listing
공시 • Oct 29Hexima Limited, Annual General Meeting, Nov 29, 2024Hexima Limited, Annual General Meeting, Nov 29, 2024. Location: at the offices of william buck, level 20, 181 william street, melbourne, vic 3000 Australia
공시 • Jul 25Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million.Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 375,000,000 Price\Range: AUD 0.02 Transaction Features: Subsequent Direct Listing
Board Change • Dec 04No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). COO & Director Nicole van der Weerden is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Nov 29Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as DirectorHexima Limited announced that Dr. Nicole van der Weerden has resigned as a director of the company effective 28 November 2023, as she pursues other endeavours.
공시 • Oct 19Hexima Limited, Annual General Meeting, Nov 28, 2023Hexima Limited, Annual General Meeting, Nov 28, 2023, at 10:00 AUS Eastern Standard Time.
공시 • Sep 20Hexima Limited Appoints Phillip Hains as A Non-Executive DirectorHexima Limited announced the appointment of Phillip Hains as a Non-Executive Director, effective 18 September 2023. Mr. Hains is a Chartered Accountant with over 30 year experience. Mr. Hains has served the needs of a number of company boards, committees and management.
Reported Earnings • Sep 02Full year 2023 earnings released: AU$0.011 loss per share (vs AU$0.066 loss in FY 2022)Full year 2023 results: AU$0.011 loss per share (improved from AU$0.066 loss in FY 2022). Revenue: AU$1.48m (down 74% from FY 2022). Net loss: AU$1.92m (loss narrowed 81% from FY 2022).
New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.3m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 34% per year over the past 5 years. Market cap is less than US$10m (AU$3.84m market cap, or US$2.49m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$4.8m revenue, or US$3.1m).
Recent Insider Transactions • Jun 07Insider recently bought AU$155k worth of stockOn the 5th of June, John Tarrant bought around 13m shares on-market at roughly AU$0.012 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
공시 • May 12Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate DirectorHexima Limited announced the resignation of Mr. Steven Skala as an alternate director of the Company, effective 11 May 2023.
Reported Earnings • Mar 04First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.029 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.029 loss in 1H 2022). Revenue: AU$1.35m (down 42% from 1H 2022). Net loss: AU$1.55m (loss narrowed 62% from 1H 2022).
공시 • Dec 22Nicole Van Der Weerden to Step Down as CEO of Hexima LimitedHexima Limited announces that Dr. Nicole van der Weerden, its Acting CEO and former COO, will step down from her executive responsibilities effective 31 December, 2022. Dr. van der Weerden will continue as a Non-Executive Director of the Company and continue to support Hexima through this transition period. This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Hexima's operational activities have been largely wound down over the past 6 months, reducing the need for a full-time CEO. The Board continues to advance its stated strategic goal of maximizing shareholder value through a transaction, supported by the Company's contract Company Secretary and contract CFO.
공시 • Dec 14+ 1 more updateHexima Limited, Annual General Meeting, Jan 31, 2023Hexima Limited, Annual General Meeting, Jan 31, 2023, at 10:00 AUS Eastern Standard Time. Location: the offices of Arnold Bloch Leibler, Level 21, 333 Collins Street Melbourne Australia Agenda: To consider to remove Mr Michael Aldridge as a Director; to consider to remove Mr Jake Nunn as a Director; to consider to remove Mr Scott Robertson as a Director; and to consider appoint Mr Chris Mews as a Director.
공시 • Dec 05Hexima Limited Announces Board ChangesHexima Limited announced the following board changes: The removal of Mr. Michael Aldridge as a director; The removal of Mr. Jake Nunn as a director; and the removal of Mr. Scott Robertson as a director.
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Non-Executive Chairman Jonathan West is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Oct 01+ 1 more updateHexima Limited, Annual General Meeting, Nov 16, 2022Hexima Limited, Annual General Meeting, Nov 16, 2022, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.066 loss per share (down from AU$0.061 loss in FY 2021). Net loss: AU$10.0m (loss widened 46% from FY 2021). Over the next year, revenue is expected to shrink by 100% compared to a 33% growth forecast for the Biotechs industry in Australia.
공시 • Aug 02Hexima Limited Announces Management ChangesHexima Limited announced that Mr. Michael Aldridge, its Managing Director & CEO, will resign his executive responsibilities effective immediately. Nicole van der Weerden, currently Chief Operating Officer, will serve as acting CEO. Mr. Aldridge will continue as a non-executive director of the Company. This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Mr. Aldridge will not be remunerated for his role as non-executive director.
공시 • Jul 12Hexima Limited Announces Phase II Results of PezadeftideHexima Limited announced the results of its phase II clinical study of pezadeftide (HXP124) for the treatment of onychomycosis (HXP124-ONY-002). HXP124-ONY-002 was designed and conducted as a phase II, multi-centre, randomized, double-blind, vehicle-controlled study to investigate the efficacy, safety and tolerability of pezadeftide (HXP124) in three dosing cohorts in patients with mild to moderate onychomycosis. Subjects were randomised to receive once daily topical application of 2% (20 mg/mL) pezadeftide or vehicle to all infected toenails in one of three cohorts (randomization 3:1 pezadeftide to vehicle): Cohort 1: 2 treatment periods of 6 weeks; N=29 pezadeftide, 9 vehicle Cohort 2: 2 treatment periods of 6 weeks plus once-weekly maintenance dosing for 23 weeks; N=30 pezadeftide, 10 vehicle Cohort 3: 5 treatment periods of 6 weeks plus 1 treatment period of 1 week; N=30 pezadeftide, 9 vehicle. A total of 117 patients were enrolled; 14 were withdrawn or dropped out prior to completing the study. Patients were assessed for safety and efficacy at scheduled visits (weeks 13, 24, 36) during the course of the study and at the final follow-up visit at week 40. Inclusion and exclusion criteria were generally consistent with those adopted in pivotal clinical studies of the leading branded topical product in the US market. There was a balanced distribution of patients between cohorts according to age, weight, height, and BMI, 80% were male, 20% female and 89% of enrolled patients were Caucasian. Completers were defined as having complied and received 85% or more of drug doses. Pezadeftide was well-tolerated and safe, with only three Serious Adverse Events (fall, angina and depression) reported and none reported as drug-related. Overall, Adverse Events (144) were primarily mild, with no unexpected Treatment Emergent Adverse Events, and were similar in reported and observed for pezadeftide and vehicle-treated patients, regardless of Cohort. The summary of efficacy as at week 40 is shown in the table below. These endpoints are the pre- defined efficacy parameters in the phase II study and are as defined by FDA. There was no consistent effect observed in pezadeftide-treated patients at week 40 compared to vehicle-treated, with the best efficacy results observed in Cohort 2.
공시 • Jun 24Hexima Limited Announces Preliminary Results of Phase II Clinical Study of PezadeftideOn June 24, 2022, Hexima Limited announced that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete.
Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Non-Executive Chairman Jonathan West is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
분석 기사 • Mar 21Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. By way of example, Hexima...
분석 기사 • Sep 06Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Jason Nunn has joined 5th company boardNon-Executive Director Jason Nunn has been appointed to the board of Hexima Limited (ASX:HXL). Nunn now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Reported Earnings • Aug 29Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.028 loss in FY 2020)Full year 2021 results: Net loss: AU$6.87m (loss widened 90% from FY 2020).
공시 • Jul 15Hexima Limited Extends Its Patent Protection for PezadeftideHexima Limited announced that a European patent covering the use of pezadeftide for the treatment of onychomycosis will be granted on 14 July 2021. The patent (#3209319) is described as "A Method of Treatment" and provides broad protection covering the therapeutic use of pezadeftide, as well as topical formulations containing pezadeftide, for the treatment of onychomycosis. The patent provides protection until 2035 and Hexima also expects to benefit from up to an additional five years of market exclusivity through the supplementary patent certification available for medicinal products in member states of the European Union. The award of this European patent further strengthens Hexima's patent portfolio which includes similar granted patents in the United States, Japan, Singapore and Australia. Hexima continues to pursue further patent filings in these and other jurisdictions; most recently receiving notification of the grant of "A Method of Treatment" patent (#382906) in Mexico.
공시 • Apr 27Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 for the Treatment of Onychomycosis at American Podiatric Medical Association Annual ConferenceHexima Limited announced that it has been selected to present clinical data from its Phase I/IIa clinical trial of HXP 124 for the treatment of onychomycosis at the annual meeting of the American Podiatric Medical Association (APMA) in Aurora, Colorado in July 2021. The APMA represents an important venue for the presentation of HXP124's potential in onychomycosis. Podiatrists are the specialists who tend to manage most cases of onychomycosis and importantly write 80% of all prescriptions for onychomycosis in the US. Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at between 10% (Japan) and 13.8% (USA). Onychomycosis is an infectious disease with significant healthcare burden, it causes pain in approximately 50% of patients and in the US results in close to four doctor's visits annually for treatment.[3] Onychomycosis impacts a patient's quality of life with 51% unable to wear the shoes they would prefer and 66% distressed by the appearance of their nail. It is important to treat onychomycosis as the fungi in the nail and can be a source of secondary infection in other areas of the body or infect family members and spread to the environment. Onychomycosis is the most common nail disorder, and the most common skin infection, accounting for 50% of all nail diseases. It is particularly prevalent in older, diabetic and immune compromised populations. The global market for treatments for onychomycosis was approximately USD 3.7 billion in 2018. Approved prescription therapies for onychomycosis comprise either oral or topical medications. Oral medications are associated with adverse effects such as nausea, taste disturbance, and flatulence. They can also severely impact liver function and so often require liver function monitoring. The clinical and commercial success of topical medications has been constrained by an inability of anti-fungal agents to effectively penetrate the human nail and the lack of sufficient anti-fungal activity when in contact with the target pathogen.
분석 기사 • Mar 02Read This Before Selling Hexima Limited (ASX:HXL) SharesWe've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
공시 • Jan 08Hexima Limited Updates Timeline to Phase 2B ResultsHexima Limited developing HXP124, a new prescription treatment for onychomycosis, announced an updated timeline to delivery of results from its phase IIb clinical trial which is being conducted in patients with onychomycosis. The pace of enrolment of patients into the trial, which is being conducted in Australia and New Zealand, has been modestly impacted by State travel restrictions, business closures and mandated lock downs due to the Coronavirus pandemic. These events have not affected in any way the integrity of the trial but are likely to result in data from the clinical trial being available one calendar quarter later than previously anticipated. Hexima has recently added additional clinical investigator sites and adopted other measures to accelerate patient recruitment and enrolment. Accordingly, Hexima expects to announce results of its phase IIb clinical trial of HXP124 in patients with onychomycosis in the second quarter of 2022.
공시 • Dec 01Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.Hexima Limited has completed an IPO in the amount of AUD 3.280771 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,403,854 Price\Range: AUD 0.2
